Continuous Ofatumumab Treatment Up to 7 Years Shows a Consistent Safety Profile and Delays Disability Progression in People with Relapsing Multiple Sclerosis (P7-1.016)
To describe long-term safety of ofatumumab and assess disability outcomes (up to 7 years) of early initiation of ofatumumab treatment versus delayed treatment (after switching from teriflunomide) in people with relapsing multiple sclerosis (pwRMS), including those recently diagnosed (≤3 years) and treatment naive (RDTN).
Authors
- Jerome De Seze (ORCID: https://orcid.org/0000-0002-7197-7578)
- Min Wu (ORCID: https://orcid.org/0000-0001-5490-3916)
- Xavier Montalbán (ORCID: https://orcid.org/0000-0002-0098-9918)
- Sarah A. Morrow (ORCID: https://orcid.org/0000-0001-7522-6440)
- Jin Nakahara (ORCID: https://orcid.org/0000-0002-5858-0998)
- Heinz Wiendl (ORCID: https://orcid.org/0000-0003-4310-3432)
- Gregory L. Pearce
- Gabriel Pardo (ORCID: https://orcid.org/0000-0002-2207-3708)
- Amit Bar‐Or (ORCID: https://orcid.org/0000-0001-7179-0335)
- Roseanne Sullivan (ORCID: https://orcid.org/0000-0001-6025-465X)
- Stephen L. Hauser (ORCID: https://orcid.org/0000-0002-4932-4001)
- Alit Bhatt
- Anil Abeyewickreme
Institutions
- Novartis (Switzerland) (CH)
- University of Calgary (CA)
- University of California, San Francisco (US)
- Keio University (JP)
- University Medical Center Freiburg (DE)
- Oklahoma Medical Research Foundation (US)
- Novartis (India) (IN)
- Novartis (United States) (US)
- Novartis (United Kingdom) (GB)
- Hotchkiss Brain Institute (CA)
- Université de Strasbourg (FR)
- University of Pennsylvania (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210474
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47